Daten werden ergänzt – lade die Seite später neu, um den aktuellen Stand zu sehen
1069498-96-9CCOC(=O)C1(CCc2ccccc2)CCN(Cc2ccc(NC(C)=O)cc2)CC1VUXRYYSKTWDPLO-UHFFFAOYSA-N1069498-96-9CHEMBL1612697Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.
BeschreibungThe μ-opioid receptor (OPRM1) is the primary site of action for morphine and other opioids associated with the treatment of pain. The occupancy of δ-opioid receptors (OPRD1) by antagonists has been shown to enhance OPRM1 binding and signaling activity. Because heteromerization of OPRM1 and OPRD1 is thought to be a potential mechanism by which this occurs, compounds are being sought that selectively activate OPRM1-OPRD1 heterodimerization while alleviating the unwanted effects associated with prolonged opiate use. ML-335 is the first identified agonist for OPRM1-OPRD1 heterodimerization (EC50 = 403 nM) that demonstrates selectivity over the individual OPRM1 and OPRD1 receptors and the serotonin HT5A receptor (EC50s = 14.9, 1.1, and >40 μM, respectively).
VerwendenML-335 is an agonist for μ-opioid receptor (OPRM1)- δ-opioid receptors (OPRD1) heterodimerization.
Keine Reaktionsaufzeichnungen unter den aktuellen Filterkriterien.
Wird geladen…